Gene-Tailored drugs aim to tackle tough bile duct cancer
NCT ID NCT07164703
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether targeted drugs or immunotherapies, chosen based on a patient's specific gene mutations, can shrink tumors and extend life in advanced cholangiocarcinoma (bile duct cancer). About 55 adults with unresectable, advanced disease and a targetable gene mutation will receive personalized treatment. The goal is to see if this precision approach improves response rates and survival compared to standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Targeted drugs or immunotherapies based on gene mutations
- What this could lead to
- If successful, this could show that matching treatments to specific gene mutations improves outcomes for people with advanced cholangiocarcinoma.
- What could go wrong
- This is an early, real-world study with only 55 participants, so results may not apply broadly. The treatments may not work for all mutation types and could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CHOLANGIOCARCINOMA (PART 1) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Provincial Hospital of Fuzhou University
Fuzhou, Fujian, 350001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.